Found 7 matching trials
Study Comparing Two Doses of MG01CI and Placebo in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder
PHASE2study objectives are to compare the efficacy, safety and tolerability of tw...
Location
Geha Medical Centre
A Phase 1 Study to Assess Pharmacokinetics of Metadoxine (MG01CI) 1400 mg, Administered to Healthy Volunteers
PHASE1objective: To assess the safety, tolerability and pharmacokinetics of metad...
Location
Clinical research center Souraski medical center
A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )
PHASE2This study is a multisite, randomized, double-blind, placebo-controlled, ph...
Location
Sarkis Clinical Trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
PHASE3This study is a multi-center, randomized, double-blind, placebo-controlled,...
Clinical Efficacy & Safety, of Metadoxine (MG01CI) Extended Release in Attention-Deficit Hyperactivity Disorder (ADHD)
PHASE2The purpose of this study is to evaluate efficacy, safety and tolerability ...
Location
Cognitive Neurology unit Rambam Health Care Campus
Safety and Tolerability Study of Metadoxine Extended Release (MDX) (Previously Known as MG01CI) in PI-ADHD Adolescent Subjects
PHASE2The purpose of this study is to evaluate the safety and tolerability of a s...
Location
Rambam Medical Center
A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome
PHASE2This study is a multisite, randomized, double-blind, placebo-controlled, ph...
Location
Southwest Autism Research & Resource Center